Advertisement

Relation between Lower Esophageal Sphincter Pressure and Plasma Concentration of Neurotensin (1–13) during Intravenous Infusion of Neurotensin (1–13) and (Gln4)-Neurotensin (1–13) in Man

  • K. Thor
  • E. Theodorsson-Norheim
  • Å Rökaeus

Abstract

Recent studies indicate that neurotensin, or a molecule with neurotensin homologies, may function as a hormone, which is released from the small intestine after the ingestion of fat (1, 2) and, among other things, may be involved in the postprandial regulation of gastrointestinal motility (3). Thus, upon intravenous infusion of (Glu4)-neurotensin (NT) or its analogue (Gln4)-neurotensin (GNT) in man, the lower esophageal sphincter (LES) pressure is reduced (4, 5), the motility in the duodenum is increased with a change in the pressure gradient between antrum and duodenum (6), the migrating motor complexes (MMC) in the proximal small intestine is inhibited with a change from a fasting- to a fed-type of motility (7) and with an increase in colonic motility (8).

Keywords

Intravenous Infusion Gastrointestinal Motility Infusion Period Intravenous Bolus Injection Colonic Motility 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Rosell, S. and Rökaeus, A. (1979). The effect of ingestion of amino acids, glucose and fat on circulating neurotensin-like immunoreactivity (NTLI) in man. Acta Physiol. Scand., 107, 263–267PubMedCrossRefGoogle Scholar
  2. 2.
    Rosell, S. and Rökaeus, A. (1981). Actions and possible hormonal functions of circulating neurotensin. Clin. Physiol., 1, 3–20CrossRefGoogle Scholar
  3. 3.
    Rosell, S., Al-Saffar, A. and Thor, K. (1983). The role of neurotensin in gut motility. Scand. J. Gastroent. In press.Google Scholar
  4. 4.
    Rosell, S., Thor, K., Rökaeus, A., Nyquist, O., Lewenhaupt, A., Kager, L. and Folkers, K. (1980). Plasma concentration of neurotensinlike immunoreactivity (NTLI) and lower esophageal sphincter (LES) pressure in man following infusion of (Gln4)-neurotensin. Acta Physiol. Scand., 109, 369–375PubMedCrossRefGoogle Scholar
  5. 5.
    Thor, K. and Rökaeus, A. (1983). Studies on the mechanisms by which (G1n4)-neurotensin reduces lower esophageal sphincter (LES) pressure in man. Acta Physiol. Scand. In press.Google Scholar
  6. 6.
    Thor, K. and Rökaeus, A. (1983). Antroduodenal motor response induced by (Gln4)-neurotensin in man. Acta Physiol. Scand. In press.Google Scholar
  7. 7.
    Thor, K., Rosell, S., Rökaeus, A. and Kager, L. (1982). (Gln4)- neurotensin changes the motility pattern of the duodenum and proximal jejunum from a fasting-type to a fed-type. Gastroenterology, 83, 569–574.PubMedGoogle Scholar
  8. 8.
    Thor, K. and Rosell, S. (1983). Neurotensin increases colonic motility. (Manuscript).Google Scholar
  9. 9.
    Al-Saffar, A. and Rosell, S. (1981). Effects of neurotensin and neurotensin analogues on the migrating myoelectrical complexes in the small intestine of rats. Acta Physiol Scand., 112, 203–208PubMedCrossRefGoogle Scholar
  10. 10.
    Theodorsson-Norheim, E. and Rosell, S. (1983). Chromatographic characterization of the increase in human plasma neurotensin-like immunoreactivity (p-NTLI) after fat ingestion. Regulatory Peptides, 6, 221–234CrossRefGoogle Scholar
  11. 11.
    Hellström, P.M. and Rosell, S. (1982). The stimulatory effect of neurotensin on colonic motility is mediated via nervous pathways. In Annals of the New York Academy of Sciences. 400, 381–383CrossRefGoogle Scholar
  12. 12.
    Al-Saffar, A. (1983). Analysis of the control of intestinal motility in fasted rats, with special reference to neurotensin. Acta Physiol. Scand. ( Submitted).Google Scholar
  13. 13.
    Theodorsson-Norheim, E., Thor, K. and Rosell, S. (1983). Relation between lower esophageal sphincter (LES) pressure and the plasma concentration of neurotensin during intravenous infusion of neurotensin (1–13) and (Gln4) neurotensin (1–13) in man. Acta Physiol. Scand. Suppl. 515, 29–35Google Scholar
  14. 14.
    Blackburn, A. and Bloom, S. (1979). A radioimmunoassay for neurotensin in human plasma. J. Endocrinol. 83, 175–181PubMedCrossRefGoogle Scholar
  15. 15.
    Blackburn, A.M., Fletcher, D.R., Adrian, T.E. and Bloom, S.E. (1980). Neurotensin infusion in man: pharmacokinetics and effect on gastrointestinal and pituitary hormones. J. Clin. Endocrinol. Metab. 51, 1257–1261PubMedCrossRefGoogle Scholar
  16. 16.
    Fletcher, D.R., Blackburn, A.M., Adrian, T.E., Chadwick, V.S. and Bloom, S.R. (1981). Effect of neurotensin on pancreatic function in man. Life Sci., 29, 2157–2161.PubMedCrossRefGoogle Scholar

Copyright information

© MTP Press Limited 1984

Authors and Affiliations

  • K. Thor
  • E. Theodorsson-Norheim
  • Å Rökaeus

There are no affiliations available

Personalised recommendations